*.*

Source link : https://www.newshealth.biz/health-news/fda-expands-durvalumab-label-to-endometrial-cancer/

The US Food and Drug Administration has expanded the indication for durvalumab (Imfinzi, AstraZeneca) to include mismatch repair deficient (dMMR) newly diagnosed advanced or recurrent endometrial cancer in combination with carboplatin and paclitaxel followed by single-agent use for maintenance. Originally approved in 2017, the programmed death ligand 1 inhibitor caries previously approved indications for non–small […]

Author : News Health

Publish date : 2024-06-17 10:24:29

Copyright for syndicated content belongs to the linked Source.

........
....................................................................................................